Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building strategies and community education programs.

NHS England » NHS to roll out long-lasting ‘suit of armour’ jab to protect thousands of premature babies from RSV ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

Nirsevimab, being developed in partnership with AstraZeneca, is the first investigational extended half-life monoclonal antibody (mAb) aiming to protect all infants entering their first RSV season ...

Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Nirsevimab, a monoclonal antibody recently approved to prevent respiratory syncytial virus-associated lower respiratory disease in newborns and infants, may protect longer than an RSV season ...

Between November 2016 and December 2017, 1447 infants were dosed (nirsevimab, n=966; placebo, n=481) at the RSV season start.1In July 2019, Sanofi and AstraZeneca initiated pivotal Phase 3 and ...

Meanwhile, 0.1% of infants in the nirsevimab group and 0.5% of infants in the standard care group were hospitalized for very severe RSV-associated lower respiratory tract infection, with an ...